PRDM1 and neoplasm: Blimp-1 was critical not only to the expression of GzmB by CD4+ T cells but also to αCTLA-4-driven anti-tumor immunity, as Blimp-1-deficient T cells were unable to control MCA205 tumor growth when mice were treated with αCTLA-4.